Biotie regains rights to develop PDE10 inhibitors for CNS disorders
19-Oct-2010
- Finland
Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about PDE10 as a novel target for the treatment of schizophrenia and other disorders of the central nervous system. We have had a succesful research collaboration with Wyeth, and then Pfizer, and together we have generated supportive data for this class. We are now in a position to pursue novel clinical candidates going forward."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.